Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGFα

British Journal of Cancer

Volumn 74, Issue 6, 1996, Pages 853-862

  Schmidt, M ^a,b   Wels, W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Directed tumour therapy; Exotoxin A; Growth factor receptor; Single chain Fv; Transforming growth factor alpha

Indexed keywords

BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; PSEUDOMONAS EXOTOXIN; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; CELL GROWTH; CELL TRANSFORMATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE C ERB; PRIORITY JOURNAL; TUMOR CELL;

EID: 0029737778     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.448     Document Type: Article

References (28)

1. BATRA JK, CHAUDHARY VK, FITZGERALD D AND PASTAN I. (1990). TGFα-anti. Tac(Fv)-PE40: a bifunctional toxin cytotoxic for cells with EGF or IL2 receptors. Biochem. Biophys. Res. Commun., 171, 1-6.
2. BATRA JK, KASPRZYK PG, BIRD RE, PASTAN I AND KING CR. (1992). Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl Acad. Sci. USA, 89, 5867-5871.
3. BEERLI RR, WELS W AND HYNES NE. (1994). Autocrine inhibition of the epidermal growth factor by intracellular expression of a single-chain antibody. Biochem. Biophys. Res. Commun., 204, 666-672.
4. CHAUDHARY VK, FITZGERALD DJ, ADHYA S AND PASTAN I. (1987). Activity of a recombinant fusion protein between transforming growth factor type α and Pseudomonas toxin. Proc. Natl Acad. Sci. USA, 84, 4538-4542.
5. CHOMCZYNSKI P AND SACCHI N. (1987). Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159.
6. COLCHER D, BIRD R, ROSELLI M, HARDMAN KD, JOHNSON S, POPE S, DODD SW, PANTOLIANO MW, MILENIC DE AND SCHLOM J. (1990). In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl Cancer Inst., 82, 1191-1197.
7. GOLDBERG MR, HEIMBROOK DC, RUSSO P, SAROSDY MF, GREENBERG RE, GIANTONIO BJ, LINEHAN WM, WALTHER M, FISHER HAG, MESSING E, CRAWFORD ED, OLIFF AI AND PASTAN IH. (1995). Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin. Cancer Res., 1, 57-61.
8. GOLDMAN R, BEN LEVI R, PELES E AND YARDEN Y (1990). Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry, 29, 11024-11028.
9. GULLICK WJ. (1991). Prevalence of abberant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull., 47, 87-98.
10. HARWERTH IM, WELS W, MARTE BM AND HYNES NE. (1992). Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as a partial ligand agonists. J. Biol. Chem., 267, 15160-15167.
11. HWANG J, FITZGERALD DJ, ADHYA S AND PASTAN I. (1987). Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E coli. Cell, 48, 129-136.
12. HYNES NE AND STERN DF. (1994). The biology of erbB-2/neu/ HER-2 and its role in cancer. Biochim. Biophys. Acta, 1198, 165-184.
13. JESCHKE M, WELS W, DENGLER W, IMBER R, STÖCKLIN E AND GRONER B. (1995). Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. Int. J. Cancer, 60, 730-739.
14. KAWAMOTO T, SATO JD, LE A, POLIKOFF J, SATO GH AND MENDELSOHN J. (1983). Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl Acad. Sci. USA, 80, 1337-1341.
15. KING CR, BORELLO I, BELLOT F, COMOGLIO P AND SCHLESSINGER J. (1988). EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumour cell line SK-BR-3. EMBO J., 7, 1647-1651.
16. c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell, 58, 287-292.
17. OGATA M, FRYLING CM, PASTAN I AND FITZGERALD DJ. (1992). Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J. Biol. Chem., 267, 25396-25401.
18. PAI LH, GALLO MG, FITZGERALD DJ AND PASTAN I. (1991). Antitumor activity of a transforming growth factor α-Pseudomonas exotoxin fusion protein (TGF-α-PE40). Cancer Res., 51, 2808-2812.
19. PELES E AND YARDEN Y. (1993). Neu and its ligands: from an oncogene to neural factors. Bioessays, 15, 815-824.
20. erbB4. Nature, 366, 473-475.
21. REAL F, RETTIG W, CHESA P, MELAMED MR, OLD LJ AND MENDELSOHN J. (1986). Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res., 46, 4726-4731.
22. RIESE DJ II, VAN RAAIJ TM, PLOWMAN GD, ANDREWS GC AND STERN DF. (1995). The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol. Cell. Biol., 15, 5770-5776.
23. SCHMIDT M, HYNES NE, GRONER B AND WELS W. (1996). A bivalent single chain antibody-toxin specific for ErbB-2 and the EGF receptor. Int. J. Cancer. 65, 538-546.
24. SIEGALL CB, XU YH, CHAUDHARY VK, ADHYA S, FITZGERALD D AND PASTAN I. (1989). Cytotoxic activities of a fusion protein comprised of TGFα and Pseudomonas exotoxin. FASEB J., 3, 2647-2652.
25. SLIWKOWSKI MX, SCHAEFER G, AKITA RW, LOFGREN JA, FITZPATRICK VD, NUIJENS A, FENDLY BM, CERIONE RA, VANDLEN RL AND CARRAWAY KL III. (1994). Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem., 269, 14661-14665.
26. SOLTOFF SP, CARRAWAY KL III, PRIGENT SA, GULLICK WG AND CANTLEY LC. (1994). ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol., 14, 3550-3558.
27. neu protein and the EGF receptor modulates EGF receptor function. Cell, 61, 1339-1347.
28. WELS W, HARWERTH IM, MUELLER M, GRONER B AND HYNES NF. (1992). Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res., 52, 6310-6317.